SAS:smm 05/28/03 899-61868

1640 # 4 DMT PATENT 8-1-02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: William H. Fleming

Application No. 10/019,165

Filed: December 20, 2001

For: METHOD FOR ENHANCING

HEMATOPOIESIS

Examiner: To be assigned

Date: May 28, 2003

Art Unit: 1642

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on May 28, 2003 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, PO BOX 1450, ALEXANDRIA, VA 22313-1450.

Susan Alpert Siegel, P Agent for Applicant

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

RECEIVED

COMMISSIONER FOR PATENTS PO BOX 1450 ALEXANDRIA, VA 22313-1450 JUN 0 4 2003

TECH CENTER 1600/2900

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent. The filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in Rule 56.

Applicant filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS.

However, if the Patent Office determines that a fee is required for Applicant to file this Information Disclosure Statement, please charge any such fees, or credit overpayment, to Deposit

SAS:smm 05/28/03 899-61868 PATENT

Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Susan Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446

SUPPLEMENTAL INFORMATION OISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	899-61868
Application Number	10/019,165
Filing Date	December 20, 2001
First Named Inventor	Fleming
Art Unit	1642
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		5,637,323	06/10/1997	Wiltrout et al.
-		5,643,741	07/01/1997	Tsukamoto et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 98/12304 A	03/26/1998	WIPORECEIVED
		EP 0 730 849 A	09/11/1996	JUN 0 4 2003
				TECH CENTER 1600/2900
Examiner's	Cite No.	OTHED DOCUMENTS		

			1 2 141 LN 1000/2900	
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS		
•		Grimee and Wulfert., "Acute stress in rats produces a rapid and sustained increase in prostacyclin production in aortic tissue: dependence on corticosterone," <i>Life Sciences</i> Vol. 57, No. 1, pp. 69-81, 1995.		
		Ohlstein et al., "SB 209670, a rationally design antagonist," <i>Proceedings of the National Act</i> 91, pp. 8052-8056, 1994.		

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.